Active Ingredient History
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Sickle Cell (Phase 1)
Arthritis, Rheumatoid (Phase 2)
Colitis, Ulcerative (Phase 3)
Demyelinating Diseases (Phase 2)
Epilepsy (Phase 2)
Graft vs Host Disease (Phase 2)
Ischemic Stroke (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Multiple Myeloma (Phase 1/Phase 2)
Multiple Sclerosis, Chronic Progressive (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Myositis (Phase 1)
Osteoarthritis, Knee (Phase 3)
Osteosarcoma (Phase 1/Phase 2)
Schizophrenia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
